Silke Tannapfel
Directeur/Membre du Conseil chez Twincore, Zentrum für Experimentelle und Klinische
Profil
Silke Tannapfel is associated with Twincore, Zentrum für Experimentelle und Klinische as a Member-Supervisory Board.
Postes actifs de Silke Tannapfel
| Sociétés | Poste | Début |
|---|---|---|
Twincore, Zentrum für Experimentelle und Klinische
 Twincore, Zentrum für Experimentelle und Klinische Miscellaneous Commercial ServicesCommercial Services Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Twincore, Zentrum für Experimentelle und Klinische
Twincore, Zentrum für Experimentelle und Klinische Miscellaneous Commercial ServicesCommercial Services Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke. | Commercial Services |
